Novartis is paying $50 million upfront to license a peptide-based radiopharmaceutical asset from China-headquartered Zonsen PepLib Biotech.
The Monday release did not name the candidate, its target or what stage of …
Read More from Endpoints News
Novartis licenses radiopharma asset from Chinese biotech for $50M upfront
